 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Xefo, Xefocam others |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | By mouth,parenteral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 90–100% |
| Protein binding | 99% |
| Metabolism | CYP2C9 |
| Eliminationhalf-life | 3–4 hours |
| Excretion | 2/3liver, 1/3kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.158.646 |
| Chemical and physical data | |
| Formula | C13H10ClN3O4S2 |
| Molar mass | 371.81 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Lornoxicam, also known aschlortenoxicam, is anonsteroidal anti-inflammatory drug (NSAID) of theoxicam class withanalgesic (pain relieving),anti-inflammatory andantipyretic (fever reducing) properties. It is available inoral andparenteral formulations.
It was patented in 1977 and approved for medical use in 1997.[1] Brand names includeXefo andXefocam among others.
Lornoxicam is used for the treatment of various types of pain, especially resulting from inflammatory diseases of the joints,osteoarthritis, surgery,sciatica, and other inflammations.[2]
The drug is contraindicated in patients who must not take other NSAIDs, possible reasons includingsalicylate sensitivity, gastrointestinal bleeding andbleeding disorders, and severe impairment of heart, liver or kidney function. Lornoxicam is not recommended during pregnancy and breastfeeding and is contraindicated during the last third of pregnancy.[2]
Lornoxicam has side effects similar to other NSAIDs, most commonly mild ones like gastrointestinal disorders (nausea anddiarrhea) andheadache. Severe but seldom side effects include bleeding,bronchospasms and the extremely rareStevens–Johnson syndrome.[2]
Interactions with other drugs are typical of NSAIDs. Combination withvitamin K antagonists likewarfarin increases the risk of bleeding. Combination withciclosporin can lead to reduced kidney function, and toacute kidney injury in rare cases. Lornoxicam can also increase the adverse effects oflithium,methotrexate anddigoxin and its derivatives. The effect ofdiuretics,ACE inhibitors andangiotensin II receptor antagonists can be reduced, but this is only relevant in patients with special risks likeheart failure. As withpiroxicam,cimetidine can increase plasma levels but is unlikely to cause relevant interactions.[3]
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key:underline indicates initially developed first-in-class compound of specific group;#WHO-Essential Medicines;†withdrawn drugs;‡veterinary use. | |
